Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma Eva Fernández-Cañabate, Sonia Fernández-Cañabate

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain José Ramón González-Porras, Francisco Javier Parrondo García, Eduardo Anguita

Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides Ana Belén Guisado-Gil, Marina Muñoz-Burgos, Ana Ortega-Eslava, Francisco Javier García-Hernández, Bernardo Santos-Ramos